Export

EN
FR
Dasatinib
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.2. Targeted therapies
ATC codes: L01EA02
EMLc
Indication
Chronic myeloid leukaemia, not elsewhere classified ICD11 code: 2C03.2
INN
Dasatinib
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Additional notes
Imatinib-resistant chronic myeloid leukaemia
Formulations
Oral > Solid: 20 mg tablet ; 50 mg tablet ; 70 mg tablet ; 80 mg tablet ; 100 mg tablet (EML) ; 140 mg tablet (EML)
EML status history
First added in 2017 (TRS 1006)
Changed in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Tags
Wikipedia
Dasatinib
DrugBank
Dasatinib
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of dasatinib 100 mg and 140 mg tablets from the EMLc.